MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $389.96 million. The enterprise value is $246.15 million.
| Market Cap | 389.96M |
| Enterprise Value | 246.15M |
Important Dates
The next confirmed earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 104.13 million shares outstanding. The number of shares has increased by 1.54% in one year.
| Shares Outstanding | 104.13M |
| Shares Change (YoY) | +1.54% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 1.30% |
| Owned by Institutions (%) | 76.40% |
| Float | 91.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.58 |
| Forward PS | 11.46 |
| PB Ratio | 1.70 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.65, with a Debt / Equity ratio of 0.08.
| Current Ratio | 10.65 |
| Quick Ratio | 9.75 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.90% and return on invested capital (ROIC) is -19.25%.
| Return on Equity (ROE) | -15.90% |
| Return on Assets (ROA) | -13.90% |
| Return on Capital (ROIC) | -19.25% |
| Revenue Per Employee | $288,727 |
| Profits Per Employee | -$265,196 |
| Employee Count | 143 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.85% in the last 52 weeks. The beta is 1.04, so MaxCyte's price volatility has been similar to the market average.
| Beta (1Y) | 1.04 |
| 52-Week Price Change | -23.85% |
| 50-Day Moving Average | 4.29 |
| 200-Day Moving Average | 4.18 |
| Relative Strength Index (RSI) | 34.71 |
| Average Volume (30 Days) | 567,698 |
Short Selling Information
The latest short interest is 3.26 million, so 3.13% of the outstanding shares have been sold short.
| Short Interest | 3.26M |
| Short Previous Month | 3.12M |
| Short % of Shares Out | 3.13% |
| Short % of Float | 3.56% |
| Short Ratio (days to cover) | 4.88 |
Income Statement
In the last 12 months, MaxCyte had revenue of $41.29 million and -$37.92 million in losses. Loss per share was -$0.37.
| Revenue | 41.29M |
| Gross Profit | 36.55M |
| Operating Income | -48.30M |
| Pretax Income | -37.92M |
| Net Income | -37.92M |
| EBITDA | -33.36M |
| EBIT | -37.92M |
| Loss Per Share | -$0.37 |
Balance Sheet
The company has $168.29 million in cash and $18.74 million in debt, giving a net cash position of $149.55 million or $1.44 per share.
| Cash & Cash Equivalents | 168.29M |
| Total Debt | 18.74M |
| Net Cash | 149.55M |
| Net Cash Per Share | $1.44 |
| Equity / Book Value | 232.17M |
| Book Value Per Share | 2.23 |
| Working Capital | 172.34M |
Cash Flow
In the last 12 months, operating cash flow was -$21.69 million and capital expenditures -$3.69 million, giving a free cash flow of -$25.38 million.
| Operating Cash Flow | -21.69M |
| Capital Expenditures | -3.69M |
| Free Cash Flow | -25.38M |
| FCF Per Share | -$0.25 |
Margins
Gross margin is 88.51%, with operating and profit margins of -116.98% and -91.85%.
| Gross Margin | 88.51% |
| Operating Margin | -116.98% |
| Pretax Margin | -91.85% |
| Profit Margin | -91.85% |
| EBITDA Margin | -80.79% |
| EBIT Margin | -91.85% |
| FCF Margin | -61.46% |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.54% |
| Shareholder Yield | -1.54% |
| Earnings Yield | -9.58% |
| FCF Yield | -6.41% |
Analyst Forecast
The average price target for MaxCyte is $8.67, which is 132.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.67 |
| Price Target Difference | 132.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 6.12 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.12 |
| Piotroski F-Score | 2 |